Background The development of HIV drug resistance and subsequent virological failure are often cited as potential disadvantages of early cART initiation. However, their long-term probability is not known, and neither is the role of duration of infection at the time of initiation. Methods Patients enrolled in the UK Register of HIV seroconverters were followed-up from cART initiation to last HIV-RNA measurement. Through survival analysis we examined predictors of virologic failure (2HIV-RNA ≥400 c/l while on cART) including CD4 count and HIV duration at initiation. We also estimated the cumulative probabilities of failure and drug resistance (from the available HIV nucleotide sequences) for early initiators (cART within 12 months of seroconversion). Results Of 1075 starting cART at a median (IQR) CD4 count 272 (190,370) cells/mm3 and HIV duration 3 (1,6) years, virological failure occurred in 163 (15%). Higher CD4 count at initiation, but not HIV infection duration at cART initiation, was independently associated with lower risk of failure (p=0.033 and 0.592 respectively). Among 230 patients initiating cART early, 97 (42%) discontinued it after a median of 7 months; cumulative probabilities of resistance and failure by 8 years were 7% (95% CI 4,11) and 19% (13,25), respectively. Conclusion Although the rate of discontinuation of early cART in our cohort was high, the long-term rate of virological failure was low. Our data do not support early cART initiation being associated with increased risk of failure and drug resistance.
References
[1]
World Health Organization (WHO). Antiretroviral therapy for HIV infection in adults and adolescents; —— (2010) revision. Available: . http://whqlibdoc.who.int/publications/20？10/9789241599764_eng.pdf . Accessed 18 April 2012.
[2]
European AIDSClinical Society (November 2012) Clinic management and treatment of HIV infected adults in Europe. Available: http://www.europeanaidsclinicalsociety.o？rg/images/stories/EACS-Pdf/EACSGuideline？s-v6.1-English-Nov2012.pdf. Accessed 05 December 2012.
[3]
British (2012) HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med; 13(S2): 1–85.
[4]
Panel on Antiretroviral Guidelines for Adults and Adolescents (2012). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March: Department of Health and Human Services. p. 1. pp. 239. Available: . http://aidsinfo.nih.gov/contentfiles/Adu？ltandAdolescentGL.pdf . Accessed 18 April 2012.
[5]
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57. doi:10.1016/S0140-6736(08)61697-9. PubMed: 19038438.
[6]
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505. doi:10.1056/NEJMoa1105243. PubMed: 21767103.
[7]
Jain V, Kwarisiima D, Liegler T, Clark T, Chamie G et al.. Changes in population-level HIV RNA distribution one year after implementation of key components of an HIV ‘test and treat’ strategy in rural Uganda. 19th International Conference on AIDS, abstract TULBE04, Washington DC (July 2012).
[8]
Uy J, Armon C, Buchacz K, Wood K, Brooks JT; HOPS Investigators (2009) Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 51:450-3.
[9]
Harrigan PRUK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group (2010) Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis 50: 1286-1287. doi:10.1086/651685. PubMed: 20353363.
[10]
Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B et al. (2005) Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191: 339-347. doi:10.1086/427192. PubMed: 15633092.
[11]
UK register of HIV seroconverters (UKRHS) Steering Committee (1996) The UK register of HIV seroconverters: methods and analytical issues. Epidemiol Infect. 117:305-12.
[12]
Royston P, Ambler G, Sauerbrei W (1999) The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 28: 964-974. doi:10.1093/ije/28.5.964. PubMed: 10597998.
[13]
Pillay D, Green H, Matthias R, Dunn D, Phillips A et al. (2005) Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J Infect Dis 192: 967-973. doi:10.1086/432763. PubMed: 16107948.
[14]
Stanford University (February 2011) HIV drug resistance database. Accessed online 22. http://hivdb.stanford.edu/.
[15]
von Wyl V, Yerly S, B？ni J, Shah C, Cellerai C et al. (2012) Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment–Naive Individuals Starting Modern Therapy Combinations. Clin Infect Dis 54: 131-140. doi:10.1093/cid/cir728. PubMed: 22057700.
[16]
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, F？tkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport CStrategies for Management of Antiretroviral Therapy (SMART) Study Group. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, et al (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296. doi:10.1056/NEJMoa062360. PubMed: 17135583.
[17]
SPARTAC Trials Investigators (2013) Short-course antiretroviral therapy in primary HIV infection. N Engl J Me 368:207-217.
[18]
Miettinen OS (1983) The need for randomization in the study of intended effects. Stat Med 2: 267-271. doi:10.1002/sim.4780020222. PubMed: 6648141.
[19]
Clements M, Law M, Pedersen C, Kaldor J, CASCADE Collaboration (2003) Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data. . ME: HIV 4:332-337.
[20]
Babiker AG, Emery S, F？tkenheuer G, Gordin FM, Grund B et al. (2012) Considerations in the rationale, design and methods of the Strategic Timing of Antiretroviral Treatment (START) study. Clin Trials 0: 1–32. PubMed: 22547421.
[21]
Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D, UK Collaborative Group on HIV Drug Resistance, UK CHIC Study GroupUK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group (2005) Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine practice. AIDS 19: 487-494 doi:10.1097/01.aids.0000162337.58557.3d. PubMed: 15764854.
[22]
Audelin AM, Lohse N, Obel N, Gerstoft J, J？rgensen LB (2009) The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 14: 995-1000. doi:10.3851/IMP1412. PubMed: 19918103.
[23]
Bannister WP, Cozzi-Lepri A, Kjaer J, Bonaventura C, Lazzarin A et al. (2011) Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother 66: 901-911. doi:10.1093/jac/dkr006. PubMed: 21393179.
[24]
Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE et al. (2000) Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 160: 1123–1132. doi:10.1001/archinte.160.8.1123. PubMed: 10789605.
[25]
Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 38: 1311-1316. doi:10.1086/383572. PubMed: 15127346.
[26]
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106. doi:10.1056/NEJMoa074609. PubMed: 18480202.
[27]
Gupta R, Hill A, Sawyer AW, Pillay D (2008) Emergence of drug resistance in HIV type 1-infected patient safer receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 47: 712-722. doi:10.1086/590943. PubMed: 18662137.
[28]
British HIV Association UK National Guidelines for HIV Testing 2008. Available: . Accessed 04 June 2013.
[29]
Health Protection Agency (November 2012) HIV in the United Kingdom: 2012 Report. London: Health Protection Services, Colindale. Available: . Accessed 04 June 2013.
[30]
Lodi S, Phillips A, Touloumi G, Pantazis , Bucher HC et al. (2010) CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS 24: 2697-2704. doi:10.1097/QAD.0b013e32833ef6c4. PubMed: 20885283.
